tbuckley/cabot-search huggingface dataset:
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
Authors: Antonio Anzueto, Igor Z. Barjaktarevic, Thomas M. Siler, Tara Rheault, Thomas Bengtsson, Kathleen Rickard, Frank Sciurba
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Ensifentrine is a novel, selective, dual phosphodiesterase (PDE)3 and PDE4 inhibitor with bronchodilator and antiinflammatory effects. Replicate phase III trials of nebulized ensifentrine were conducted (ENHANCE-1 and ENHANCE-2) to assess these effects in patients with chronic obstructive pulmonary disease (COPD).
Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure
Authors: Maryam AlKhatry, Babusai Rapaka, Daniel B. Maselli, Donna Maria Abboud, Vitor O. Brunaldi, Tala Mahmoud, Rabih Ghazi, Farah Abdul Razzak, Khushboo Gala, Imad Joudah, Fedaa Housen, Sana Al Qadi, Eric J. Vargas, Andrew C. Storm, Barham K. Abu Dayyeh
Journal: Endoscopy (2023)

The primary obesity surgery endoluminal 2.0 (POSE 2.0) procedure involves full-thickness gastric body plications to narrow the stomach using durable suture anchor pairs. We evaluated POSE 2.0 as a treatment strategy for nonalcoholic fatty liver disease (NAFLD) in patients with obesity.Adults with obesity and NAFLD were prospectively allocated based on their preference to undergo POSE 2.0 with lifestyle modification or lifestyle modification alone (control). Primary end points were improvement in controlled attenuation parameter (CAP) and resolution of hepatic steatosis at 12 months. Secondary end points included %total body weight loss (%TBWL), change in serum measures of hepatic steatosis and insulin resistance, and procedure safety.42 adult patients were included (20 in the POSE 2.0 arm and 22 in the control arm). At 12 months, POSE 2.0 significantly improved CAP, whereas lifestyle modification alone did not (P < 0.001 for POSE 2.0; P = 0.24 for control). Similarly, both resolution of steatosis and %TBWL were significantly higher with POSE 2.0 than with control at 12 months. Compared with controls, POSE 2.0 significantly improved liver enzymes, hepatic steatosis index, and aspartate aminotransferase to platelet ratio at 12 months. There were no serious adverse events. CONCLUSION : POSE 2.0 was effective for NAFLD in patients with obesity, with good durability and safety profile.
Cardiorenal interactions in heart failure: insights from recent therapeutic advances
Authors: Kevin Damman, Jeffrey Testani
Journal: Cardiovascular Research (2023)

Abstract Heart failure is a syndrome that may develop when cardiovascular disease progresses or is insufficiently treated and associated with a poor quality of life, high mortality rates, and increased healthcare expenditures. Prevention and treatment of heart failure are therefore of utmost importance. New therapies in patients with cardiovascular disease have recently been shown to be effective in the prevention and sometimes treatment of heart failure, and additional research is underway. Specifically, in high-risk patients with either (a combination of) diabetes, chronic kidney disease, and/or heart failure, three specific drug classes [sodium–glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1-RAs), and non-steroidal mineralocorticoid receptor antagonists (MRAs)] have taken centre stage in therapeutic approach for these high cardiovascular risk patients. The commonality of these drugs is the finding that they improve cardiovascular and renal endpoints across the cardiorenal continuum and SGTL2i have already proved effective in all subtypes of heart failure, while we await data on non-steroidal MRA therapy in heart failure. The story may be different for GLP-1-RA in patients with established heart failure, but these drugs are effective in reducing cardiovascular events in patients with diabetes. Taken together, these new therapies advance the treatment and improve the associated outcomes of patients with cardiorenal disease and diabetes, with similar characteristics and effectiveness in different conditions.
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Authors: Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, Qiwei Wu, Yu Du, Sirel Gurbuz, Tamer Coskun, Axel Haupt, Zvonko Milicevic, Mark L. Hartman
Journal: New England Journal of Medicine (2023)

Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known.We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed.We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Journal: Journal of Clinical Oncology (2023)

In Figures 1C and1D, the fulvestrant KM curves are same as the curves in panels A and B. Figure 1C and 1D have been replaced.
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
Authors: Nicoletta Colombo, Toon Van Gorp, Ursula A. Matulonis, Ana Oaknin, Rachel N. Grisham, Gini F. Fleming, Alexander B. Olawaiye, Dorothy D. Nguyen, Andrew E. Greenstein, Joseph M. Custodio, Hristina I. Pashova, Iulia C. Tudor, Domenica Lorusso
Journal: Journal of Clinical Oncology (2023)

Despite therapeutic advances, outcomes for patients with platinum-resistant/refractory ovarian cancer remain poor. Selective glucocorticoid receptor modulation with relacorilant may restore chemosensitivity and enhance chemotherapy efficacy.This three-arm, randomized, controlled, open-label phase II study (ClinicalTrials.gov identifier: NCT03776812) enrolled women with recurrent, platinum-resistant/refractory, high-grade serous or endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer, or ovarian carcinosarcoma treated with ≤4 prior chemotherapeutic regimens. Patients were randomly assigned 1:1:1 to (1) nab-paclitaxel (80 mg/m2) + intermittent relacorilant (150 mg the day before, of, and after nab-paclitaxel); (2) nab-paclitaxel (80 mg/m2) + continuous relacorilant (100 mg once daily); or (3) nab-paclitaxel monotherapy (100 mg/m2). Nab-paclitaxel was administered on days 1, 8, and 15 of each 28-day cycle. The primary end point was progression-free survival (PFS) by investigator assessment; objective response rate (ORR), duration of response (DOR), overall survival (OS), and safety were secondary end points.A total of 178 women were randomly assigned. Intermittent relacorilant + nab-paclitaxel improved PFS (hazard ratio [HR], 0.66; log-rank test P = .038; median follow-up, 11.1 months) and DOR (HR, 0.36; P = .006) versus nab-paclitaxel monotherapy, while ORR was similar across arms. At the preplanned OS analysis (median follow-up, 22.5 months), the OS HR was 0.67 (P = .066) for the intermittent arm versus nab-paclitaxel monotherapy. Continuous relacorilant + nab-paclitaxel showed numerically improved median PFS but did not result in significant improvement over nab-paclitaxel monotherapy. Adverse events were comparable across study arms, with neutropenia, anemia, peripheral neuropathy, and fatigue/asthenia being the most common grade ≥3 adverse events.Intermittent relacorilant + nab-paclitaxel improved PFS, DOR, and OS compared with nab-paclitaxel monotherapy. On the basis of protocol-prespecified Hochberg step-up multiplicity adjustment, the primary end point did not reach statistical significance (P < .025). A phase III evaluation of this regimen is underway (ClinicalTrials.gov identifier: NCT05257408).
Clarithromycin-containing triple therapy for <i>Helicobacter pylori</i> eradication is inducing increased long-term resistant bacteria communities in the gut
Authors: Olga Sjomina, Reinis Vangravs, Elīna Ļeonova, Inese Poļaka, Dārta Pūpola, Kristaps Čivkulis, Aleksandra Jeniceka, Sergejs Paršutins, Ilmārs Stonāns, Jin Young Park, Lars Engstrand, Mārcis Leja
Journal: Gut (2023)
Persistent villous atrophy predicts development of complications and mortality in adult patients with coeliac disease: a multicentre longitudinal cohort study and development of a score to identify high-risk patients
Authors: Annalisa Schiepatti, Stiliano Maimaris, Suneil A Raju, Olivia L Green, Giulia Mantica, Amelie Therrien, David Flores-Marin, Justin Linden, Fernando Fernández-Bañares, Maria Esteve, Daniel Leffler, Federico Biagi, David S Sanders
Journal: Gut (2023)

Persistent villous atrophy (pVA) in coeliac disease (CD) despite a gluten-free diet (GFD) has unclear meaning. We aimed to (i) study the relationship between pVA and long-term outcomes and (ii) develop a score to identify patients at risk of pVA.This is a multicentre retrospective-prospective study consisting of a study cohort (cohort 1) and an external validation cohort (cohort 2) of patients with biopsy-proven CD diagnosed between 2000 and 2021. Cohort 1 was used to (i) compare long-term outcomes between patients with and without pVA (Marsh ≥3a) at follow-up biopsy and (ii) to develop a score to evaluate the risk of pVA, which was validated in cohort 2.Of 2211 patients, 694 (31%) underwent follow-up duodenal biopsy and were included in the study cohort (491F, 44±16 years). 157/694 (23%) had pVA. Risk of complications (HR 9.53, 95% CI 4.77 to 19.04, p<0.001) and mortality (HR 2.93, 95% CI 1.43 to 6.02, p<0.01) were increased in patients with pVA. A 5-point score was developed and externally validated (receiver operating characteristic area under the curve 0.78, 95% CI 0.68 to 0.89) to stratify patients by risk of pVA: low (0-1 points, 5% pVA), intermediate (2 points, 16% pVA) and high (3-5 points, 73% pVA). Predictors for pVA used in the score were age at diagnosis ≥45 years (OR 2.01, 95% CI 1.21 to 3.34, p<0.01), classical pattern of CD (OR 2.14, 95% CI 1.28 to 3.58, p<0.01), lack of clinical response to GFD (OR 2.40, 95% CI 1.43 to 4.01, p<0.001) and poor GFD adherence (OR 48.9, 95% CI 26.1 to 91.8, p<0.001).Risk of complications and mortality were increased in patients with pVA. We developed a score to identify patients at risk of pVA and in need of histological reassessment and closer follow-up.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Authors: W Timothy Garvey, Juan P Frias, Ania M Jastreboff, Carel W le Roux, Naveed Sattar, Diego Aizenberg, Huzhang Mao, Shuyu Zhang, Nadia N Ahmad, Mathijs C Bunck, Imane Benabbad, Xiaotian M Zhang, Franklin H. Abalos, Federico C.P. Manghi, Cesar J. Zaidman, Marisa L. Vico, Diego Aizenberg, Pablo R. Costanzo, Leonardo P. Serra, Ignacio J. MacKinnon, Miguel N. Hissa, Maria H. Vidotti, Jose F. Kerr Saraiva, Breno B. Alves, Denise R. Franco, Otavio Moratto, Sreenivasa Murthy, Ghanshyam Goyal, Yoshimitsu Yamasaki, Nobuyuki Sato, Satoshi Inoue, Taro Asakura, Marina Shestakova, Elena Khaykina, Ekaterina Troshina, Natalia Vorokhobina, Alexander Ametov, Shih-Te Tu, Chwen-Yi Yang, I-Te Lee, Chien-Ning Huang, Horng-Yih Ou, George Freeman, Sriram Machineni, Klara Klein, Senan Sultan, Alan Parsa, Juan Otero-Martinez, Alex Gonzalez, Anuj Bhargava, Susan Brian, Carlos Ince, Stephen Plantholt, Jeremy Cole, Audrey Lacour, Damaris Vega, Jose de Souza, Jane L. Rohlf, Roy C. St. John, Barry Horowitz, Hanid Audish, Rodolfo Galindo, Guillermo Umpiperrez, Jamy Ard, Brian Curtis, William T. Garvey, Neil J. Fraser, Jose Mandry, Rizwana Mohseni, Ronald Mayfield, Talessa Powell, Carl Vance, Stephen Ong, Ana L. Lewy-Alterbaum, Alexander Murray, Amer Al-Karadsheh, Tamer Yacoub, Kevin Roberts, David L. Fried, Julio Rosenstock, Bharathi Pulla, Bruce Bode, Juan Frias, Leslie Klaff, Ronald Brazg, Joanna Van, Anjanette Tan, Toby Briskin, Margaret Rhee, Tira Chaicha-Brom, Paul A. Hartley, Lazaro Nunez, Gregorio Cortes-Maisonet, Gary Soucie, Stanley Hsia, Thomas Jones
Journal: The Lancet (2023)
Gene therapy advances shine the spotlight on epidermolysis bullosa, bringing hope to patients
Authors: Ulrich Koller
Journal: Molecular Therapy (2023)

Recent breakthroughs in gene therapy continue to transform the landscape of therapies for epidermolysis bullosa (EB), offering encouraging outcomes for patients suffering from this severe blistering skin disease. Two different therapeutic strategies that have already reached the clinic share the common goal of restoring the missing or dysfunctional protein via gene replacement. Notably, while ex vivo approaches have shown success in the past, a ground-breaking in vivo gene therapy product has recently gained approval from the US Food and Drug Administration, marking a significant milestone for EB therapy.
Blocking IL-6 signaling improves glucose tolerance via SLC39A5-mediated suppression of glucagon secretion
Authors: Wenli Chen, Weiyi Cui, Jianhong Wu, Wen Zheng, Xueting Sun, Jie Zhang, Haibao Shang, Ye Yuan, Xue Li, Jue Wang, Xinli Hu, Liangyi Chen, Fanxin Zeng, Rui-Ping Xiao, Xiuqin Zhang
Journal: Metabolism (2023)
Re-administration of AAV vectors by masking with host albumin: A Goldilocks hypothesis
Authors: J. Fraser Wright
Journal: Molecular Therapy (2023)

Strategies to administer AAV vectors safely and effectively to subjects with pre-existing antibodies are needed because of the high prevalence of wild-type AAV infection and increasing use of AAV-based products. Capsid antibodies block transduction, are cross-reactive between serotypes, 1 Kruzik A. Fetahagic D. Hartlieb B. Dorn S. Koppensteiner H. Horling F.M. Scheiflinger F. Reipert B.M. de la Rosa M. Prevalence of anti adeno-associated virus immune responses in international cohorts of healthy donors. Mol. Ther. Methods Clin. Dev. 2019; 14: 126-133 Abstract Full Text Full Text PDF PubMed Scopus (99) Google Scholar and recipients of AAV vectors generate high-titer antibodies that are durable for years. 2 George L.A. Ragni M.V. Rasko J.E.J. Raffini L.J. Samelson-Jones B.J. Ozelo M. Hazbon M. Runowski A.R. Wellman J.A. Wachtel K. et al. Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol. Ther. 2020; 28: 2073-2082 Abstract Full Text Full Text PDF PubMed Scopus (113) Google Scholar Immune complexes formed by antibody binding to AAV have been implicated in activation of the complement cascade 3 Zaiss A.K. Cotter M.J. White L.R. Clark S.A. Wong N.C.W. Holers V.M. Bartlett J.S. Muruve D.A. Complement is an essential component of the immune response to adeno-associated virus vectors. J. Virol. 2008; 82: 2727-2740 Crossref PubMed Scopus (107) Google Scholar associated with serious adverse events in high-dose clinical trials. Strategies to overcome this problem include discovery or creation of novel, immunologically distinct capsids 4 Bartel M. Schaffer D. Büning H. Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front. Microbiol. 2011; 2: 204https://doi.org/10.3389/fmicb.2011.00204 Crossref PubMed Scopus (82) Google Scholar that have the potential to increase the number of subjects eligible for a first-time treatment but will themselves induce high-titer antibodies that preclude AAV vector re-administration. Removal of AAV antibodies in subjects before vector administration by plasmapheresis, in vivo enzymatic digestion of total IgG, and prevention of antibody formation by immune suppression are promising approaches 5 Schulz M. Levy D.I. Petropoulos C.J. Bashirians G. Winburn I. Mahn M. Somanathan S. Cheng S.H. Byrne B.J. Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy. Mol. Ther. 2023; 31: 616-630 Abstract Full Text Full Text PDF PubMed Scopus (16) Google Scholar but may not achieve sufficient antibody reduction and pose additional risks. Solving the antibody problem is key to maximize AAV gene therapy safety, efficacy, and wide utilization, including enablement of re-dosing to maintain the benefit achieved after an initial systemic dose that delivers therapeutic genes to liver or neuro-muscular cells but that fades with time or pediatric patient growth.
Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations
Authors: Binni Kunvarjee, Alan Bidgoli, Rebecca Pellett Madan, Esther Vidal, Devin McAvoy, Kinga K. Hosszu, Andromachi Scaradavou, Barbara G. Spitzer, Kevin J. Curran, Maria Cancio, Andrew C. Harris, Richard J. O’Reilly, Andrew L. Kung, Susan Prockop, Jaap Jan Boelens, Joseph H. Oved
Journal: Journal of Allergy and Clinical Immunology (2023)
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Authors: Julio Rosenstock, Juan Frias, Ania M Jastreboff, Yu Du, Jitong Lou, Sirel Gurbuz, Melissa K Thomas, Mark L Hartman, Axel Haupt, Zvonko Milicevic, Tamer Coskun
Journal: The Lancet (2023)
Inhaled corticosteroids to improve lung function in children (aged 6–12 years) who were born very preterm (PICSI): a randomised, double-blind, placebo-controlled trial
Authors: Rhea C Urs, Denby J Evans, Tiffany K Bradshaw, James T D Gibbons, Elizabeth F Smith, Rachel E Foong, Andrew C Wilson, Shannon J Simpson
Journal: The Lancet Child & Adolescent Health (2023)
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial
Authors: Margaret V Ragni, Scott D Rothenberger, Robert Feldman, Danielle Nance, Andrew D Leavitt, Lynn Malec, Roshni Kulkarni, Robert Sidonio, Eric Kraut, Joseph Lasky, Rajiv Pruthi, Dana Angelini, Claire Philipp, Nina Hwang, Allison P Wheeler, Craig Seaman, Nicoletta Machin, Frederico Xavier, Michael Meyer, Daniel Bellissimo, Gregory Humphreys, Kenneth J Smith, Elizabeth P Merricks, Timothy C Nichols, Dana Ivanco, Deborah Vehec, Glory Koerbel, Andrew D Althouse
Journal: The Lancet Haematology (2023)
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study
Authors: Ana P M Canton, Flávia R Tinano, Leonardo Guasti, Luciana R Montenegro, Fiona Ryan, Deborah Shears, Maria Edna de Melo, Larissa G Gomes, Mariana P Piana, Raja Brauner, Rafael Espino-Aguilar, Arancha Escribano-Muñoz, Alyssa Paganoni, Jordan E Read, Márta Korbonits, Carlos E Seraphim, Silvia S Costa, Ana Cristina Krepischi, Alexander A L Jorge, Alessia David, Lena R Kaisinger, Ken K Ong, John R B Perry, Ana Paula Abreu, Ursula B Kaiser, Jesús Argente, Berenice B Mendonca, Vinicius N Brito, Sasha R Howard, Ana Claudia Latronico
Journal: The Lancet Diabetes & Endocrinology (2023)
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
Authors: Pegah Golabi, James M. Paik, Ameeta Kumar, Reem Al Shabeeb, Kathrine E. Eberly, Kenneth Cusi, Nagashree GunduRao, Zobair M. Younossi
Journal: Metabolism (2023)
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/<i>TP53</i>mut
Authors: Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Othman Al-Sawaf, Karl-Anton Kreuzer, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood (2023)
Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression
Authors: Ryan P. Jajosky, Kashyap R. Patel, Jerry William L. Allen, Patricia E. Zerra, Satheesh Chonat, Diyoly Ayona, Cheryl L. Maier, Dominique Morais, Shang-Chuen Wu, C. John Luckey, Stephanie C. Eisenbarth, John D. Roback, Ross M. Fasano, Cassandra D. Josephson, John P. Manis, Li Chai, Jeanne E. Hendrickson, Krystalyn E. Hudson, Connie M. Arthur, Sean R. Stowell
Journal: Blood (2023)
Generation of functionally distinct T-cell populations by altering the viscoelasticity of their extracellular matrix
Authors: Kwasi Adu-Berchie, Yutong Liu, David K. Y. Zhang, Benjamin R. Freedman, Joshua M. Brockman, Kyle H. Vining, Bryan A. Nerger, Andrea Garmilla, David J. Mooney
Journal: Nature Biomedical Engineering (2023)
Distinct metabolic requirements regulate B cell activation and germinal center responses
Authors: Rahul Sharma, Ryan M. Smolkin, Priyanka Chowdhury, Keith Conrad Fernandez, Youngjun Kim, Montserrat Cols, William Alread, Wei-Feng Yen, Wei Hu, Zhong-Min Wang, Sara Violante, Ronan Chaligné, Ming O. Li, Justin R. Cross, Jayanta Chaudhuri
Journal: Nature Immunology (2023)
Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect
Authors: Kento Umino, Kaoru Morita, Takashi Ikeda, Shin-ichiro Kawaguchi, Takashi Nagayama, Shoko Ito, Daisuke Minakata, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Shin-ichiro Fujiwara, Shun-ichi Kimura, Shinichi Kako, Noriko Doki, Yukiyasu Ozawa, Yasuo Mori, Tetsuya Eto, Nobuhiro Hiramoto, Hirohisa Nakamae, Junya Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Hideki Nakasone, Satoko Morishima, Yoshinobu Kanda
Journal: Blood (2023)